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Abstract 
Subcellular microvesicles (MVs) have attracted increasing interest during the past decades. While initially consid-
ered as inert cellular debris, several important roles for MVs in physiological homeostasis, cancer, cardiovascular, and 
autoimmune diseases have been uncovered. Although still poorly understood, MVs are involved in trafficking of 
information from cell-to-cell, and are implicated in the regulation of immunity, thrombosis, and coagulation. Differ-
ent subtypes of extracellular MVs exist. This review focuses on the cell membrane-derived shedded MVs (ranging in 
size from 200 to 1000 nm) typically termed microparticles (MPs). The numbers and particularly the composition of 
MPs appear to reflect the state of their parental cells and MPs may therefore carry great potential as clinical biomark-
ers which can be elucidated and developed by proteomics in particular. Determination of the identity of the specific 
proteins and their quantities, i.e. the proteome, in complex samples such as MPs enables an in-depth characterization 
of the phenotypical changes of the MPs during disease states. At present, only a limited number of proteomic studies 
of circulating MPs have been carried out in healthy individuals and disease populations. Interestingly, these studies 
indicate that a small set of MP-proteins, in particular, overexpression of galectin-3-binding protein (G3BP) distinguish 
MPs in patients with venous thromboembolism and the systemic autoimmune disease, systemic lupus erythemato-
sus (SLE). G3BP is important in cell–cell adhesion, clearance, and intercellular signaling. MPs overexpressing G3BP may 
thus be involved in thrombosis and hemostasis, vascular inflammation, and autoimmunity, further favoring G3BP as 
a marker of “pathogenic” MPs. MPs expressing G3BP may also hold a potential as biomarkers in other conditions such 
as cancer and chronic viral infections. This review highlights the methodology and results of the proteome studies 
behind these discoveries and places them in a pathophysiological and biomarker perspective.
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Introduction: microvesicles–microparticles
Microvesicles (MVs) are a heterogenous population of 
submicron membranous vesicles released from all types 
of cells both constitutively and during activation and 
apoptosis [1]. MVs are released from cytosolic organelles, 
such as granules, from the endoplasmic reticulum, and 
from multivesicular bodies and are also shed directly 
from the cell surface membrane [1]. Even though the field 
is rapidly growing, the limited knowledge about the dif-
ferent types of MVs, their formation, composition, fate, 
and function still hampers the definitions, terminology, 
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and studies. The MVs that derive from the multivesicular 
bodies are termed exosomes and range in size from 40 to 
100 nm, while the larger MVs (200–1000 nm) shed from 
the cell surface are typically termed microparticles (MPs) 
[1]. In this review, we focus on human MP studies based 
on this definition.
MPs are composed of a complex mixture of proteins, 
glycoproteins, lipids, and RNA/DNA [2]. They carry 
many bioactive molecules, and their structure which is 
reminiscent of liposomes enhances their co-stimula-
tory properties similar to adjuvants in vaccines [3]. MPs 
interact with other cells, platelets, other MPs, and the 
extracellular matrix and facilitate intercellular communi-
cation. As examples, MPs can shuttle mRNA and miRNA 
to acceptor cells and regulate their protein translation, 
MPs serve as a major mobilizable reservoir of tissue fac-
tor (TF) and can initiate coagulation, and MPs can alter 
immune responses in autoimmune diseases, e.g. by trig-
gering dendritic cells to release interferon-α (IFN-α), a 
major effector cytokine in systemic lupus erythematosus 
(SLE) [1, 4, 5]. Most functional studies have been con-
ducted in vitro by investigating subsets of MPs or specific 
surface molecules from MPs induced in cultured cells [6]. 
Functional MP studies ex vivo have been few [5]. Instead, 
investigations in patients have focused on quantitat-
ing cellular subsets of circulating MPs and correlating 
them to a specific disease or disease manifestation and 
thereby explore their pathogenic roles and/or biomarker 
potential [7]. Generally, MPs increase in numbers dur-
ing cellular activation or apoptosis, but determining their 
numbers and origin have not proved specific or sensitive 
enough for biomarker use. More extensive and detailed 
characterization of the specific MP subpopulations is 
highly needed. Until now most studies have character-
ized MP subpopulations using cell-specific surface mark-
ers due to the paucity of other identified markers specific 
for subsets of MPs involved e.g. in pathological processes 
[8–10].
Unbiased in-depth characterization of DNA/RNA con-
tent, lipids, metabolites, and proteins may help unravel 
the MP-composition and the discovery of new markers 
of MPs that are involved in disease pathogenesis. Here, 
we review the methodology and results of proteomic dis-
covery studies of human plasma MPs. We argue that a 
restricted set of candidate MP proteins, galectin-3-bind-
ing protein (G3BP) in particular, could prove highly use-
ful as biomarkers and tools to understanding the role 
of MPs in the systemic autoimmune disease, systemic 
lupus erythematosus (SLE), and venous thromboembo-
lism (VTE), and potentially also in cancer and chronic 
viral infections [8, 11–15]. G3BP is a cysteine-rich scav-
enger receptor [16, 17]. G3BP exerts its regulatory roles 
by binding to lectins, extracellular matrix proteins, and 
integrins [18–20]. G3BP is upregulated during cell activa-
tion, viral infections, cell death, and in cancer cells, and 
G3BP-expression could reflect an aberrant state of the 
parental cells, e.g. apoptosis [21–24]. In HIV and hepati-
tis C, serum G3BP has been associated with a poorer out-
come [22, 25–28]. G3BP plays important roles in cell–cell 
adhesion and intercellular signaling in the immune sys-
tem and in cancer and metastasis [29–32]. Breast cancer 
cells in  vitro release G3BP which promotes tumor cell 
aggregation and inhibition of peri-tumor fibrosis ulti-
mately favoring metastasis [31, 33, 34]. In line with these 
observations, serum G3BP is associated with a poorer 
prognosis in non-Hodgkin lymphoma, lung and breast 
cancer [33, 35, 36]. In this review we focus on G3BP-
expressing MPs in SLE and VTE. However, G3BP may 




The design, pre-analytical and analytical methodol-
ogy, and the results of the circulating human MP pro-
teome studies to date are presented in detail in Table 1. 
In all cases the MPs were isolated by centrifugation from 
plasma, in some cases combined with prior size exclu-
sion chromatography. It must be noted, however, that 
the exact conditions (to the extent they are specified) 
differ, i.e. different anticoagulants and—in particular—
different centrifugation conditions (time, temperature, 
volumes, and g-forces) were used. This makes it difficult 
to compare studies, even those that aim to characterize 
and establish MP proteomes of healthy individuals [37–
40]. So far, only one study has attempted a systematic 
optimization of MP isolation steps monitored by objec-
tive parameters such as number and reproducibility of 
protein identifications [40]. The incomparability of data 
between studies of circulating MPs in normal controls is 
compounded by the vastly different analytical conditions 
and data extraction methods (Table  1). Many studies 
rely on liquid chromatography–tandem mass spectrom-
etry (LC–MS/MS) with no labeling and other studies 
use isobaric tags for relative and absolute quantitation 
(iTRAQ) or isotope-coded affinity tags (ICAT). Further, 
some studies use 1-D or 2-D gel electrophoresis as pri-
mary separation and then MALDI-qTOF MS or other 
MALDI-TOF configurations. The resulting number of 
identified proteins in normal circulating MPs conse-
quently varies considerably from 151 [12] to more than 
530 [11] and contrasts to the more than 1100 common 
proteins identified in studies on platelet MPs [41]. Also, 
only rudimentary information on reproducibility within 
and between runs is available. Further, no reference 
ranges of MP numbers, types and protein abundance 
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have been established in any population or patient group 
so far. Every study is a compromise between how exten-
sively (how deeply) MP proteomes are characterized 
and the analysis time required for this weighed against 
the number of samples. This may favor pooling of sam-
ples in some cases but this should only be done after 
careful consideration of pros and cons [42]. Due to the 
complexity and heterogeneity of the MP compartment 
in blood samples some studies concentrate on the MPs 
produced by platelets, erythrocytes, or granulocytes. This 
is accomplished either by culturing the cells and studying 
the MPs they release after various stimuli or by isolating 
(e.g. by immunoaffinity methods) the specific MPs from 
plasma by virtue of their surface markers. By far the larg-
est group of this type of studies deal with platelet-MPs 
derived from platelets isolated by centrifugation and then 
subjected to stimuli such as ADP, thrombin, and/or col-
lagen [11–16]. Platelet MPs are normally among the most 
numerous in the circulation and are important in cardio-
vascular events both in venous and arterial thrombosis. 
Characterization of the ensemble of circulating MPs in 
plasma is addressed wholly or partly in eight of the stud-
ies included in Table 1 [17–24].
The microparticle protein composition reflects the state 
of the parental cell
Since the composition of MPs appears to reflect the state 
of the parental cell, the actual biomarker potential lies 
within unravelling compositional changes of MPs dur-
ing disease states [43]. Mass spectrometry-based analysis 
has a great potential to decipher the dynamic compo-
nents of MP proteomes. Thus, Peterson et al. [44] showed 
that approximately 10% of the proteins are differentially 
expressed in endothelial cell-derived MPs from human 
umbilical vascular endothelial cells (HUVECs) depending 
on the activation stimuli [tumor necrosis factor (TNF) 
or plasminogen activator inhibitor (PAI)]. Similar obser-
vations have been made in cultured non-malignant and 
malignant cell-lines, monocytes, erythrocytes, and plate-
lets. Bernimoulin et al. stimulated monocytic THP-1 cells 
with lipopolysaccharide (LPS) or a soluble P-selectin 
chimera [45]. Fifty-two and 408 proteins were uniquely 
expressed in the corresponding MP fractions. In particu-
lar, differential expression of proteins from subcellular 
Iocations such as mitochondria and adhesion molecules 
were enriched in MP-fractions from the soluble P-selec-
tin chimera stimulated cells. Another study, comparing 
the proteome of MPs from platelets stimulated by either 
shear-stress or by thrombin, revealed that 26 proteins 
were differentially expressed [46]. These proteins were 
particularly related to cell assembly and organization 
and to cell morphology. In line with this, Milioli et  al. 
[41] found that the platelet-derived MP protein content 
was highly dependent on the type of physiological ago-
nist involved in platelet stimulation [thrombin, adeno-
sine diphosphate (ADP), or collagen]. Interestingly, 
activation with stronger agonists resulted in platelet MP 
(PMP) overexpression of proteins related to platelet acti-
vation, while proteins involved in platelet degranulation 
and proteins from the electron transport chain were less 
abundant. In red blood cells, Prudent et al. [47] observed 
that calcium dependent proteins and annexins 4 and 5 
were recruited in MPs generated by calcium stimulation 
compared to stored red blood cells (>40  days storage). 
In neutrophils, more than 400 distinct proteins could be 
identified in MPs released from neutrophils either in sus-
pension (stimulated with fMLF, formyl-methionyl-leucyl 
phenylalanine), or adherent to a HUVEC monolayer, 
with only 223 proteins overlapping in the two MP-frac-
tions [10]. Thus, mass spectrometry can uncover baseline 
and induced MP proteomes and pinpoint MP candidate 
biomarkers.
Proteomics of human circulating microparticles identifies 
galectin-3 binding protein as a candidate biomarker 
for pathogenic microparticles
The human MP proteome studies to date have explored 
the proteome of the whole pool of plasma MPs, eryth-
rocyte- (eMPs) or platelet-derived MPs (PMPs) isolated 
directly from plasma, or MPs generated in  vitro from 
isolated platelets or granulocytes in healthy or diseased 
individuals [10–12, 37–41, 46, 48–56]. As can be seen 
from Table  1 the pre-analytical and analytical protocols 
differ between the studies on almost all points and cau-
tion regarding their interpretation is therefore warranted. 
The major observations are highlighted and put into per-
spective in the following sections.
Healthy individuals
Smalley et  al. [38] observed that G3BP was more abun-
dant in the total fraction of plasma MPs compared to 
the subfraction of platelet-derived MPs from healthy 
individuals. They also found an increased abundance of 
immunoglobulins, complement proteins, alpha-2-mac-
roglobulin (A2M), and CD5 antigen-like protein in the 
total MP fraction. Together with this observation, the 
absence or very low abundance of G3BP in other pro-
teomic studies of platelets, platelet- or erythrocyte-
derived MPs during healthy conditions suggests that 
G3BP expression is a distinct feature of MPs derived 
from nucleated cells such as leukocytes and/or endothe-
lial cells [37, 38, 41, 46, 49–53, 56]. In contrast to G3BP, 
A2  M was also found in erythrocyte-derived MPs and 
PMPs [52].
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Systemic lupus erythematosus
SLE is an immune complex-mediated autoimmune dis-
ease linked to defective clearance of apoptotic cells, 
and circulating MPs are putative sources and traffick-
ers of extracellular nuclear autoantigens. Østergaard 
et  al. observed that circulating MPs from patients with 
SLE had increased quantities of G3BP compared to 
patients with systemic sclerosis and rheumatoid arthritis 
and to healthy controls [11, 57]. Ficolin-2, 14-3-3, β-2-
glycoprotein-I, CD5 antigen-like protein, immunoglobu-
lins, and complement proteins were also overabundant in 
SLE-MPs. Notably, A2M was not overexpressed. Overall, 
these findings suggested that more circulating MPs in 
SLE are of apoptotic origin and derive from leukocytes 
or endothelial cells, carry large quantities of autoantigens 
and immune complexes (ICs), and, finally, that G3BP is a 
distinguishing feature of such pathogenic MPs.
Venous thromboembolism
Ramacciotti et al. [12] found that G3BP was also enriched 
in plasma MPs in nine patients with deep venous throm-
bosis (DVT) compared to nine patients with leg pain 
without DVT and to six healthy controls. Also, comple-
ment proteins, immunoglobulins, A2M, CD5 antigen-like 
protein, clusterin, and polymeric immunoglobulin recep-
tor were increased in MPs from DVT patients. It should 
be noted that in this study the samples were analysed 
three times and only A2M and G3BP were consistently 
identified in all three experiments in each patient. DeRoo 
et al. [58] explored the role of G3BP and galectin-3 (gal-
3) in a mouse model of venous thromboembolism (VTE). 
Here they found G3BP in MPs, platelets, red blood cells, 
the thrombi and vein walls but not in leukocytes using 
quantitative immunoblotting and qRT-PCR. They did 
not observe a difference between the VTE and non-VTE 
mice regarding G3BP-MP quantities. Interestingly, signif-
icant levels of G3BP was found on the endothelium and 
bound to gal-3 on neutrophils facilitating their migration 
and extravasation. Gal-3 appeared to drive the vascular 
inflammation by stimulating the production of interleu-
kin-6 and chemokine (C-C motif ) ligand 2 (CCL2). This 
links both G3BP and gal-3 to inflammatory changes 
in VTE. In experimental VTE using four baboons, the 
same research group showed that fibrinogen and α1-anti-
chymotrypsin were enriched and some immunoglobu-
lins were down-regulated two days after a 6 h occlusion 
of the iliac veins [59]. G3BP was not enriched. The MP 
proteome in experimental rat VTE showed increased 
abundance of fibrinogens, macroglobulins including 
A2M, and immunoglobulins [60]. Thus, animal studies do 
not reproduce the findings of a G3BP-increase in human 
DVT; the interpretation of this discrepancy remains 
elusive.
Atherosclerosis
Several roles for MPs in the acceleration of atherosclero-
sis and arterial thrombosis have been proposed [4]. Mayr 
et al. [61] explored the proteome of MPs from atheroscle-
rotic plaques. They found that the MPs were primarily of 
leukocyte origin based on the presence of surface markers 
(CD14, CD11c, CD18, CD51, and CD36), but that some 
also derived from smooth muscle cells and erythrocytes. 
Interestingly, immunoglobulins were also very abundant 
but primarily confined to the interior of the MPs, espe-
cially in MPs of macrophage origin, and the marked dif-
ference between antigen specificity compared to plasma 
immunoglobulins suggested a specific binding of anti-
bodies to MP antigens [61]. Little et al. [39] characterized 
the plasma MP proteome in 42 individuals, the majority 
with a history of cardiovascular disease, hypertension, 
and diabetes. A core set of proteins was identified and 
correlated to gender and age, but, surprisingly, not to the 
other available cardiovascular risk factors. G3BP did not 
correlate with age and gender corroborating the utility of 
G3BP as an age/gender independent disease biomarker. 
Interestingly, at the same time the research group filed a 
patent application on G3BP as soluble biomarker for car-
diovascular disease (patent application title and number: 
Galectin-3-Binding Protein as a Biomarker of Cardiovas-
cular Disease, 20100055723) and recently observed that 
plasma G3BP correlated to mortality in coronary artery 
disease [62]. In patients with lacunar infarction, plasma 
MPs were characterized and correlated to clinical out-
come and compared to healthy controls [55]. A differen-
tial expression of 43 proteins was observed. In particular, 
myelin basic protein was upregulated. G3BP and CD5 
antigen-like protein were downregulated, while A2M 
showed minimal alterations. It should be noted that the 
MP isolation protocol differs significantly from the other 
protocols and most likely also includes a large propor-
tion of exosomes (see Table 1 for details). Thus, based on 
a limited amount of data, an overexpression of G3BP on 
MPs in atherosclerosis or cardiovascular disease cannot 
be demonstrated.
A distinct overlap of the disease‑associated microparticle 
proteomes in SLE and DVT patients
Despite the fact that so far only few and small studies 
with significant differences in methodology have been 
conducted, there is a striking overlap of MP-overex-
pressed proteins across the different disease entities, in 
particular G3BP, immunoglobulins, complement pro-
teins, A2M, and CD5 antigen-like protein. Interestingly, 
G3BP and CD5 antigen-like protein were the only two 
common proteins found upregulated in plasma MPs, 
DVT, and SLE patient MP proteomes, while the common 
denominators in DVT and SLE were G3BP and A2M 
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[11, 12, 38]. Accordingly, G3BP is the only consistently 
enriched protein across these three studies. Additionally, 
immunoglobulins and complement proteins were also 
found consistently enriched in the DVT and SLE MPs. 
SLE patients exhibit an increased platelet and coagula-
tion activity and increased incidence of venous throm-
bosis. Altogether, these observations implicate MPs 
expressing these proteins as being involved in the disease 
pathogenesis and also suggest that these particular MPs 
originate from nucleated cells [10, 63, 64].
Galectin-3-binding protein: structure, formation, 
and function
The formation, targets and biological functions of galec-
tin-3-binding protein (also named Mac-2-binding pro-
tein) are yet not well defined. G3BP has been detected in 
several types of body fluids, such as serum, breast milk 
and semen, and is expressed in most tissues [18, 32]. In 
plasma, G3BP circulates in association with MPs as well 
as large soluble ring-like oligomers 30–40  nm in diam-
eter with a molecular size larger than 1000 kDa [18, 39]. 
In vitro, G3BP is up-regulated by interferon (IFN)-α and 
-γ, viruses, and double-stranded polynucleotides [14, 23, 
65]. Accordingly, plasma G3BP have been found elevated 
in diseases with increased IFN activity such as human 
immunodeficiency virus infection, chronic viral hepa-
titis, and SLE, but also in various types of solid cancers, 
Behcet’s disease, and rheumatoid arthritis [14, 66–72]. 
G3BP serves as a scavenger receptor which interacts 
with several targets [16]. It was originally identified (and 
named) in the search for gal-3 glycoprotein ligands [16, 
17, 20]. Galectins are a group of 15 different carbohy-
drate binding proteins (lectins), termed galectin-1 (gal-1) 
to galectin-15 [13]. Gal-1 and gal-3 are involved in cell 
growth, adhesion, differentiation, inflammation, fibrosis, 
apoptosis, and metastasis [13]. Galectins bind via carbo-
hydrate binding domains to galactosides on cell surfaces 
and on extracellular glycoproteins [64]. G3BP is heavy 
glycosylated and, as a major receptor for gal-3 and gal-
1, it may be crucial for galectin mediated biological pro-
cesses [18, 73]. Additionally, G3BP exhibits independent 
and selective binding to components of the extracellular 
matrix of the basement membrane in solid-phase assays, 
i.e. it interacts with collagen V and VI, fibronectin and 
nidogen, but not with laminin-1, fibulin-1 and -2, perle-
can, and BM-40 [18]. G3BP also mediates cell–cell adhe-
sion through binding to β1-integrin and LPS-dependently 
to CD14, and the protein seems to exert regulatory roles 
in immunity, e.g. through up-regulation of major histo-
compatibility class I (MHC-I) molecules and through the 
ability to stimulate natural killer (NK-) cells [18, 19, 32].
Collectively, G3BP is involved in the initiation and 
promotion of cell–cell adhesion and pro-inflammatory 
signalling cascades in viral infections, cancer (includ-
ing metastasis), coagulation and haemostasis, and 
autoimmunity.
The origin, role, and biomarker potential 
of G3BP-expressing microparticles
The proteomic studies of plasma MPs from disease enti-
ties characterized by some degree of intravascular cell 
death and activation combined with systemic and local 
inflammation, activation of the coagulation system, 
and thrombophilia suggest a common MP pathologi-
cal proteome profile. Besides G3BP, these profiles also 
include immunoglobulins, complement proteins, A2M, 
and CD5 antigen-like protein. These observations sug-
gest that MPs are tagged for removal during pathological 
states and that the overabundance of these proteins could 
reflect common upstream pathogenic processes such as 
increased cell activation and apoptosis in the circulating 
cells or endothelium along with activation of the coagula-
tion and immune system.
The cellular origin of G3BP-expressing microparticles
The cellular origin of G3BP-positive MPs under various 
conditions remains to be established. G3BP has been 
identified in high abundance in leukocytes, endothe-
lial cells, and red blood cells and has been undetectable 
or present at a low abundance in platelets or platelet-
derived MPs in humans. The G3BP gene expression is 
also dominant in type I IFN-activated neutrophils and 
peripheral blood mononuclear cells (PBMCs) in SLE 
patients [66]. In contrast, in a mouse model (C57CL/6 
strain) G3BP was detected in platelets, circulating MPs, 
red blood cells, but not leukocytes [58]. This underscores 
the difficulty of translating animal studies of the molecu-
lar pathology of thrombosis (and SLE) to human systems. 
The available data from studies in humans strongly sug-
gest that the majority of the G3BP-overexpressing MPs 
in the circulation originate from neutrophils, monocytes, 
and endothelial cells.
The mechanisms behind microparticle 
G3BP-overexpression
G3BP overexpression on MPs most likely reflects the 
state of the parental cells, i.e. activation, stress, or, death. 
During these processes, G3BP is relocated into MPs and/
or binds to upregulated MP surface molecules e.g. to 
gal-1 or gal-3. Generally, the composition and packaging 
of MPs is highly coordinated [7]. Increased G3BP asso-
ciated with MPs may be caused by increased loading of 
G3BP during MP production in parent cells and tissues 
and/or increased binding of exogenous G3BP, e.g. from 
the circulation, to released MPs. As an example of dif-
ferential expression, Dalli et al. only found low quantities 
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of G3BP in MPs from fMLF-stimulated neutrophils and 
G3BP could not be detected in MPs originating from 
neutrophils stimulated by HUVECs. In contrast to the 
low G3BP expression generated by these stimuli, type I 
IFNs induce G3BP gene expression in vitro, and explora-
tory studies of IFN gene signatures in neutrophils and 
PBMCs from SLE patients identified G3BP as one of only 
few highly IFN-inducible genes [66, 74, 75]. However, it 
is unsettled if IFN activation results in increased G3BP 
in/on MPs, or, indeed, if systemic inflammation per se 
leads to increase in plasma-G3BP and a correspond-
ing increase in binding of G3BP to MPs. Several studies 
suggest that increased MP-G3BP expression is part of 
the defence against viral infection [23, 74]. One possibil-
ity is that the virus-infected cells increase G3BP expres-
sion to eliminate viral particles by shedding G3BP-tagged 
MPs containing viral particles that are recognized and 
removed by professional phagocytes in the reticuloen-
dothelial system. In our proteomic studies G3BP was 
the only IFN-inducible protein overabundant in SLE-
MPs indicating that other mechanisms than type I IFN-
induction controls MP-G3BP expression [11]. It is likely 
that G3BP overexpression simply reflects an increased 
number of apoptotic cell-derived circulating MPs in SLE 
patients. Lectins serve as sensors of apoptotic cells due to 
surface glycosylation changes on such cells. Accordingly, 
galectins significantly increase their binding to apoptotic 
cells, and G3BP subsequently binds to the galectins [63, 
64]. In support of the notion of G3BP MPs being of apop-
totic origin we found that G3BP is co-localized with glo-
merular immune complex deposits and on singular round 
structures in kidney biopsies from SLE patients [8]. As 
mentioned previously, apoptotic cells and MPs are major 
sources of extracellular autoantigens in the immune com-
plex deposits, and the significant presence of G3BP in 
these deposits and on circulating MPs strongly corrobo-
rate the apoptotic origin of G3BP MPs [8, 76, 77]. Studies 
of the expression of G3BP on MPs from cells undergoing 
apoptosis or stimulated with IFN are needed to clarify 
the relative contributions of different cellular processes 
to the increase of G3BP-positive MPs in SLE and vascular 
disease.
The role of G3BP-expressing microparticles in systemic 
lupus erythematosus
SLE is a systemic autoimmune disease capable of affect-
ing most organ systems including the kidneys where 
glomerulonephritis (termed lupus nephritis, LN) is 
the major severe manifestation. Development of SLE is 
linked to defective clearance of apoptotic cells leading 
to an excess of highly auto-immunogenic cellular debris 
(apoptotic bodies and MPs) triggering anti-nuclear auto-
immunity [8, 78–82]. An early important pathological 
feature is the occurrence of immune complex deposits in 
the glomerular basement membrane (GBM) that activate 
the complement system and incite inflammation [76, 83, 
84]. Thus it is highly interesting to clarify the origin of 
these ICs in order to prevent their production and dep-
osition and the subsequent inflammation and progres-
sion of LN. The origin of the ICs in the GBM is, however, 
unsettled. They may derive either from the circulation 
or locally in the glomeruli or even from a combination. 
The identification of G3BP as part of large MP-IC assem-
blies circulating in the blood of SLE patients is highly 
interesting in this context [57]. As mentioned, G3BP 
binds strongly to gal-1 and gal-3 and integrins, which are 
upregulated on endothelial cells, and also to basement 
membrane proteins [18]. Accordingly, G3BP may endow 
these MP-ICs with significant cell- and basement mem-
brane adhesive properties in addition to affecting acti-
vation of immune cells. By binding to the endothelium 
and the extracellular matrix of the basement membrane 
G3BP may contribute to the MP-IC deposition and accu-
mulation in the kidney [18, 19, 23, 32, 57, 85]. This may 
be aggravated by increased type I IFN-induced G3BP. 
Under normal conditions, G3BP may be part of the nor-
mal cell and MP clearance. However, the increased type 
I IFNs and G3BP in combination with a constant excess 
of highly altered immunogenic MPs may be crucial for 
the breakdown of tolerance and sustained systemic auto-
immunity of SLE. Whether G3BP also could have adju-
vant effects on the cellular arms of the immune system 
enhancing the stimulation by the MP-associated autoan-
tigens is unclear. In any case, because of this multitude of 
possible pathogenetic mechanisms involving G3BP, this 
protein is an interesting putative therapeutic target [77]. 
By targeting G3BP the MP-autoantigenic “fuel” could 
be blocked reducing the IC deposition, activation of the 
complement system and the cellular arms of the immune 
system. This approach could prove more specific and 
thus less toxic and less prone to side effects than tradi-
tional immuno-suppressants.
Galectin-3-binding protein and venous thromboembolism
VTE occurs as a result of blood stasis, hypercoagulabil-
ity, and increased pro-coagulant adhesion molecules on 
endothelial cells in conjunction with inflammation. Cir-
culating MPs are pro-coagulant and can contribute to 
thrombosis by their exposure of TF and phosphatidylser-
ine [4]. Soluble, cell-, and MP-exposed gal-3 and G3BP 
may modulate thrombogenesis, particularly the involved 
inflammatory cascades, and are interesting future thera-
peutic targets [13].
It has been become apparent that inflammation con-
tributes to VTE. In a study by deRoo and coworkers, acti-
vated platelets expressed P-selectin and PSGL-1 that lead 
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to increased leukocyte adhesion and thrombus forma-
tion. Binding of G3BP to gal-1 on the platelets resulted in 
an increased P-selectin expression and promoted plate-
let activation and thrombogenesis [58]. This may trigger 
increased MP-G3BP release and perpetuate the platelet 
activation. Also, G3BP and gal-3 affected the cell–cell 
adhesion on the thrombus-endothelial interface and the 
thrombus itself and were increased on the endothelium 
in a mouse model of VTE [58]. Additionally, in this study, 
during early VTE gal-3 was greatly increased and G3BP 
and gal-3 co-localized in the leukocyte/endothelial cell 
interface and leukocytes were attached to the vein wall. 
The thrombus size correlated with gal-3 and interleukin-6 
in the vein wall, and the vein wall inflammatory changes 
seemed driven by triggering of IL-6 by gal-3 and the pro-
inflammatory chemokine CCL2. In patients with acute 
VTE elevated levels of circulating G3BP were found. 
Accordingly, G3BP seems to play a role in the pathogen-
esis of VTE and thrombophilia. In SLE increased rates of 
VTE are a prominent feature and G3BP may be a novel 
thrombophilia risk factor independent of the presence 
of anti-phospholipid antibodies. We have also observed 
that increased levels of plasma G3BP were a predictor 
of venous thromboembolic events in SLE patients inde-
pendent of the presence of anti-phospholipid antibod-
ies (unpublished data). Clarification of the role of G3BP 
needs further exploration in VTE. If further studies sup-
port an important role for G3BP in thrombosis the devel-
opment of G3BP or gal-3 blocking compounds seems to 
be attractive future therapeutic approaches.
G3BP-expressing microparticles as future biomarkers
Generally, in inflammatory and thrombotic diseases 
G3BP-overexpressing MPs appear to be promising diag-
nostic or prognostic biomarkers as well as biomarkers of 
disease activity. Additionally, G3BP-MPs could be sensi-
tive novel biomarkers of apoptotic activity relevant in 
autoimmunity, cardiovascular disease, and cancer.
Specifically, MP-associated G3BP may represent several 
advantages compared with soluble plasma G3BP used as 
biomarkers. Total plasma G3BP and G3BP-MPs levels do 
not completely mirror each other [14]. This suggests that 
G3BP is differentially expressed in different compart-
ments in the blood. Mass spectrometry provides a global 
measure of G3BP in a whole pool of pelleted MPs. Dif-
ferent populations of G3BP-positive MPs based on G3BP 
and PS surface densities can be discerned in the circula-
tion in both healthy individuals and SLE patients using 
flow cytometry [14]. Only one of the flow cytometrically 
identified G3BP-positive populations correlated with 
plasma G3BP levels, while there were no apparent cor-
relation between plasma G3BP and the MP G3BP quan-
tities obtained by mass spectrometry. In SLE, G3BP-MP 
expression distinguished SLE patients from healthy con-
trols and from patients with other autoimmune diseases 
(systemic sclerosis and rheumatoid arthritis) and it seems 
worthwhile to test the diagnostic potential in larger pro-
spective cohorts of patients presenting with signs of sys-
temic connective tissue disease [11]. In relation to disease 
activity, clinical, or immunological manifestations, there 
was no correlation to the G3BP-MP quantities obtained 
by mass spectrometry [14]. The concentrations of one of 
the flow cytometrically identified sub-populations (G3BP 
and annexin V positive) correlated to anti-dsDNA lev-
els but not to disease activity or to clinical or serologi-
cal manifestations [8]. This links G3BP-expressing MPs 
to polyclonal activation of plasma cells or the effects 
thereof, but their use as biomarkers of disease activity 
seems limited in SLE.
In VTE increased levels of d-dimer are sensitive mark-
ers of VTE, but are, however, not specific. G3BP-MPs 
may contribute to the specificity, perhaps as part of an 
MP-DVT profile with A2M and CD5 antigen-like pro-
tein. In VTE little focus has been on monitoring, damage 
and outcome and a role for G3BP as a biomarker here is 
difficult to predict.
Plasma levels of G3BP may reflect macrophage activ-
ity and type I IFN activity [14, 15]. To a certain degree 
this may also be the case for G3BP-expressing MPs. Type 
I IFNs are associated with subclinical markers of ath-
erosclerosis in vitro [86, 87]. Thus it interesting that the 
plasma concentrations of G3BP are significantly asso-
ciated with the degree of subclinical atherosclerosis in 
patients with HIV and hepatitis C [15]. This may also be 
the case in SLE, where increased type I IFNs and accel-
erated atherosclerosis are dominant features. Recently, 
plasma G3BP levels were independently associated with 
long-term cardiovascular mortality [62]. Little et al. [39] 
do not report on the putative correlations between the 
G3BP MP quantities and cardiovascular comorbidities, 
which would be interesting area to explore for future ath-
erosclerosis biomarker studies.
Conclusions
The unbiased dissection of the circulating MP proteome 
has led to novel discoveries of candidate MP proteins 
associated with venous thrombosis and systemic lupus 
erythematosus. These include G3BP, immunoglobu-
lins, complement, A2M, and CD5 antigen-like protein. 
In general, the candidate MP biomarkers provide new 
tools to explore the roles of MPs in disease pathogen-
esis and as biomarkers. The restricted number of dif-
ferentially expressed MP proteins fit the notion that 
the proteins reflect the specific state of their parental 
cells. Accordingly, the MP-proteins serve as biomark-
ers for MPs that either reflect or have direct roles in 
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the disease pathogenesis, i.e. patho-phenotypical or 
pathogenic MPs, respectively. In SLE, high IFN-activity 
and improper clearance of apoptotic cells may lead to 
the overabundance of apoptotic-derived MPs with high 
expression of G3BP that form large circulating immune 
complexes. G3BP on the surface of the MPs most likely 
facilitates the deposition of the MP-ICs in the kidney 
promoting glomerulonephritis. MP-G3BP may thus 
have a direct role in SLE pathogenesis, while also serv-
ing as a biomarker in lupus nephritis, and of circulating 
apoptotic-derived MPs. While the proteomic studies 
clearly associate MP-G3BP overexpression with SLE and 
deep venous thrombosis, we anticipate that the future 
potential of G3BP and the other MP candidate biomark-
ers may be even far greater in cancer and chronic viral 
diseases. A major limitation of the proteome discovery 
studies is often the small number of patients and con-
trols. With the identification of the MP-biomarkers, the 
proteins can now be easily incorporated in large MP-
biomarker panels together with cell-specific markers, 
annexin V, or other MP molecules of interest enabling 
high-throughput targeted MP studies in large cohorts of 
patients. Such large studies are now feasible and highly 
warranted in the fields of coagulation and hemostasis, 
infection, cancer, and autoimmunity.
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